Browsing: EGFRMutated

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss how to counsel patients who are hesitant to continue…

In this segment, Dr. Alexander Spira introduces a second patient case involving a 62-year-old woman with resectable stage IIIA EGFR-mutated…

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss which outcomes are most clinically meaningful when evaluating neoadjuvant…

In this segment, Dr. Alexander Spira and Dr. Natalie Vokes explore the impact of neoadjuvant targeted therapy on surgical planning…

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss how to approach the transition from neoadjuvant therapy to…

In this closing segment, Dr. Alexander Spira and Dr. Edward Kim reflect on key takeaways from the patient case discussions,…

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal focus on the importance of multidisciplinary coordination in managing early-stage…

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss how clinicians interpret EGFR tyrosine kinase inhibitor (TKI) data…

In this segment, Dr. Alexander Spira and Dr. Natalie Vokes examine how outcomes with adjuvant EGFR tyrosine kinase inhibitors translate…

In this segment, Dr. Alexander Spira engages Dr. Natalie Vokes in a discussion on the distinct biology of EGFR-mutated non–small…